{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T19:14:03Z","timestamp":1795029243599,"version":"4.10.2"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,2,14]],"date-time":"2022-02-14T00:00:00Z","timestamp":1644796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,2,14]],"date-time":"2022-02-14T00:00:00Z","timestamp":1644796800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81801052"],"award-info":[{"award-number":["81801052"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["61633018"],"award-info":[{"award-number":["61633018"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82020108013"],"award-info":[{"award-number":["82020108013"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Plasma amyloid-\u03b2 (A\u03b2) may facilitate identification of individuals with brain amyloidosis. Gut microbial dysbiosis in Alzheimer\u2019s disease (AD) is increasingly being recognized. However, knowledge about alterations of gut microbiota in preclinical AD, as well as whether the combination of plasma A\u03b2 and gut microbiota could identify preclinical AD, remains largely unknown.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This study recruited 34 A\u03b2-negative cognitively normal (CN\u2212) participants, 32 A\u03b2-positive cognitively normal (CN+) participants, and 22 patients with cognitive impairment (CI), including 11 patients with mild cognitive impairment (MCI) and 11 AD dementia patients. All participants underwent neuropsychological assessments and fecal microbiota analysis through 16S ribosomal RNA (rRNA) Illumina Miseq sequencing technique. Meso Scale Discovery (MSD) kits were used to quantify the plasma A\u03b2\n                      <jats:sub>40<\/jats:sub>\n                      , A\u03b2\n                      <jats:sub>42<\/jats:sub>\n                      , and A\u03b2\n                      <jats:sub>42<\/jats:sub>\n                      \/A\u03b2\n                      <jats:sub>40<\/jats:sub>\n                      in CN\u2212 and CN+ participants. Using Spearman\u2019s correlation analysis, the associations of global standard uptake value rate (SUVR) with altered gut microbiota and plasma A\u03b2 markers were separately evaluated. Furthermore, the discriminative power of the combination of gut microbiota and plasma A\u03b2 markers for identifying CN+ individuals was investigated.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Compared with the CN\u2212 group, the CN+ group showed significantly reduced plasma A\u03b2\n                      <jats:sub>42<\/jats:sub>\n                      (\n                      <jats:italic>p<\/jats:italic>\n                      = 0.011) and A\u03b2\n                      <jats:sub>42<\/jats:sub>\n                      \/A\u03b2\n                      <jats:sub>40<\/jats:sub>\n                      (\n                      <jats:italic>p<\/jats:italic>\n                      = 0.003). The relative abundance of phylum\n                      <jats:italic>Bacteroidetes<\/jats:italic>\n                      was significantly enriched, whereas phylum\n                      <jats:italic>Firmicutes<\/jats:italic>\n                      and class\n                      <jats:italic>Deltaproteobacteria<\/jats:italic>\n                      were significantly decreased in CN+ individuals in comparison with that in CN\u2212 individuals. Particularly, the relative abundance of phylum\n                      <jats:italic>Firmicutes<\/jats:italic>\n                      and its corresponding SCFA-producing bacteria exhibited a progressive decline tendency from CN\u2212 to CN+ and CI. Besides, the global brain A\u03b2 burden was negatively associated with the plasma A\u03b2\n                      <jats:sub>42<\/jats:sub>\n                      \/A\u03b2\n                      <jats:sub>40<\/jats:sub>\n                      (\n                      <jats:italic>r<\/jats:italic>\n                      = \u22120.298,\n                      <jats:italic>p<\/jats:italic>\n                      = 0.015), family\n                      <jats:italic>Desulfovibrionaceae<\/jats:italic>\n                      (\n                      <jats:italic>r<\/jats:italic>\n                      = \u22120.331,\n                      <jats:italic>p<\/jats:italic>\n                      = 0.007), genus\n                      <jats:italic>Bilophila<\/jats:italic>\n                      (\n                      <jats:italic>r<\/jats:italic>\n                      = \u22120.247,\n                      <jats:italic>p<\/jats:italic>\n                      = 0.046), and genus\n                      <jats:italic>Faecalibacterium<\/jats:italic>\n                      (\n                      <jats:italic>r<\/jats:italic>\n                      = \u22120.291,\n                      <jats:italic>p<\/jats:italic>\n                      = 0.018) for all CN participants. Finally, the combination of plasma A\u03b2 markers, altered gut microbiota, and cognitive performance reached a relatively good discriminative power in identifying individuals with CN+ from CN\u2212 (AUC = 0.869, 95% CI 0.782 ~ 0.955).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study provided the evidence that the gut microbial composition was altered in preclinical AD. The combination of plasma A\u03b2 and gut microbiota may serve as a non-invasive, cost-effective diagnostic tool for early AD screening. Targeting the gut microbiota may be a novel therapeutic strategy for AD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>\n                      This study has been registered in ClinicalTrials.gov (NCT03370744,\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.clinicaltrials.gov\">https:\/\/www.clinicaltrials.gov<\/jats:ext-link>\n                      ) in November 15, 2017.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13195-022-00977-x","type":"journal-article","created":{"date-parts":[[2022,2,14]],"date-time":"2022-02-14T06:09:56Z","timestamp":1644818996000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":83,"title":["Combination of gut microbiota and plasma amyloid-\u03b2 as a potential index for identifying preclinical Alzheimer\u2019s disease: a cross-sectional analysis from the SILCODE study"],"prefix":"10.1186","volume":"14","author":[{"given":"Can","family":"Sheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beiqi","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenying","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanning","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0377-7424","authenticated-orcid":false,"given":"Ying","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,2,14]]},"reference":[{"key":"977_CR1","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.jalz.2017.12.006","volume":"14","author":"J Jia","year":"2018","unstructured":"Jia J, Wei C, Chen S, Li F, Tang Y, Qin W, et al. The cost of Alzheimer's disease in China and re-estimation of costs worldwide. Alzheimers Dement. 2018;14:483\u201391.","journal-title":"Alzheimers Dement"},{"key":"977_CR2","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack Jr","year":"2018","unstructured":"Jack CR Jr, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA research framework: toward a biological definition of Alzheimer's disease. Alzheimers Dement. 2018;14:535\u201362.","journal-title":"Alzheimers Dement"},{"key":"977_CR3","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s13024-020-00395-3","volume":"15","author":"X Wang","year":"2020","unstructured":"Wang X, Huang W, Su L, Xing Y, Jessen F, Sun Y, et al. Neuroimaging advances regarding subjective cognitive decline in preclinical Alzheimer's disease. Mol Neurodegener. 2020;15:55.","journal-title":"Mol Neurodegener"},{"key":"977_CR4","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/S0140-6736(15)01124-1","volume":"388","author":"P Scheltens","year":"2016","unstructured":"Scheltens P, Blennow K, Breteler MM, de Strooper B, Frisoni GB, Salloway S, et al. Alzheimer's disease. Lancet. 2016;388:505\u201317.","journal-title":"Lancet."},{"key":"977_CR5","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/S1474-4422(19)30356-4","volume":"19","author":"JF Cryan","year":"2020","unstructured":"Cryan JF, O'Riordan KJ, Sandhu K, Peterson V, Dinan TG. The gut microbiome in neurological disorders. Lancet Neurol. 2020;19:179\u201394.","journal-title":"Lancet Neurol"},{"key":"977_CR6","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1152\/physrev.00018.2018","volume":"99","author":"JF Cryan","year":"2019","unstructured":"Cryan JF, O'Riordan KJ, Cowan CSM, Sandhu KV, Bastiaanssen TFS, Boehme M, et al. The microbiota-gut-brain axis. Physiol Rev. 2019;99:1877\u20132013.","journal-title":"Physiol Rev"},{"key":"977_CR7","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/nyas.13416","volume":"1420","author":"E Sherwin","year":"2018","unstructured":"Sherwin E, Dinan TG, Cryan JF. Recent developments in understanding the role of the gut microbiota in brain health and disease. Ann N Y Acad Sci. 2018;1420:5\u201325.","journal-title":"Ann N Y Acad Sci"},{"key":"977_CR8","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.neurobiolaging.2016.08.019","volume":"49","author":"A Cattaneo","year":"2017","unstructured":"Cattaneo A, Cattane N, Galluzzi S, Provasi S, Lopizzo N, Festari C, et al. Association of brain amyloidosis with pro-inflammatory gut bacterial taxa and peripheral inflammation markers in cognitively impaired elderly. Neurobiol Aging. 2017;49:60\u20138.","journal-title":"Neurobiol Aging"},{"key":"977_CR9","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.exger.2018.12.005","volume":"115","author":"D Abraham","year":"2019","unstructured":"Abraham D, Feher J, Scuderi GL, Szabo D, Dobolyi A, Cservenak M, et al. Exercise and probiotics attenuate the development of Alzheimer's disease in transgenic mice: role of microbiome. Exp Gerontol. 2019;115:122\u201331.","journal-title":"Exp Gerontol"},{"key":"977_CR10","doi-asserted-by":"publisher","first-page":"2426","DOI":"10.1038\/s41598-017-02587-2","volume":"7","author":"L Bonfili","year":"2017","unstructured":"Bonfili L, Cecarini V, Berardi S, Scarpona S, Suchodolski JS, Nasuti C, et al. Microbiota modulation counteracts Alzheimer's disease progression influencing neuronal proteolysis and gut hormones plasma levels. Sci Rep. 2017;7:2426.","journal-title":"Sci Rep"},{"key":"977_CR11","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/j.bbi.2019.05.008","volume":"80","author":"P Liu","year":"2019","unstructured":"Liu P, Wu L, Peng G, Han Y, Tang R, Ge J, et al. Altered microbiomes distinguish Alzheimer's disease from amnestic mild cognitive impairment and health in a Chinese cohort. Brain Behav Immun. 2019;80:633\u201343.","journal-title":"Brain Behav Immun"},{"key":"977_CR12","doi-asserted-by":"publisher","first-page":"13537","DOI":"10.1038\/s41598-017-13601-y","volume":"7","author":"NM Vogt","year":"2017","unstructured":"Vogt NM, Kerby RL, Dill-McFarland KA, Harding SJ, Merluzzi AP, Johnson SC, et al. Gut microbiome alterations in Alzheimer's disease. Sci Rep. 2017;7:13537.","journal-title":"Sci Rep"},{"key":"977_CR13","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1016\/j.jalz.2019.07.002","volume":"15","author":"B Li","year":"2019","unstructured":"Li B, He Y, Ma J, Huang P, Du J, Cao L, et al. Mild cognitive impairment has similar alterations as Alzheimer's disease in gut microbiota. Alzheimers Dement. 2019;15:1357\u201366.","journal-title":"Alzheimers Dement"},{"key":"977_CR14","doi-asserted-by":"publisher","first-page":"513","DOI":"10.3233\/JAD-210259","volume":"82","author":"C Sheng","year":"2021","unstructured":"Sheng C, Lin L, Lin H, Wang X, Han Y, Liu SL. Altered gut microbiota in adults with subjective cognitive decline: the SILCODE study. J Alzheimer\u2019s Dis. 2021;82:513\u201326.","journal-title":"J Alzheimer's Dis."},{"key":"977_CR15","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.jalz.2014.07.001","volume":"11","author":"V Chouraki","year":"2015","unstructured":"Chouraki V, Beiser A, Younkin L, Preis SR, Weinstein G, Hansson O, et al. Plasma amyloid-\u03b2 and risk of Alzheimer's disease in the Framingham Heart Study. Alzheimers Dement. 2015;11:249\u201357.e1.","journal-title":"Alzheimers Dement"},{"key":"977_CR16","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1016\/j.jalz.2018.01.004","volume":"14","author":"O Hanon","year":"2018","unstructured":"Hanon O, Vidal JS, Lehmann S, Bombois S, Allinquant B, Tr\u00e9luyer JM, et al. Plasma amyloid levels within the Alzheimer's process and correlations with central biomarkers. Alzheimers Dement. 2018;14:858\u201368.","journal-title":"Alzheimers Dement"},{"key":"977_CR17","doi-asserted-by":"publisher","first-page":"365","DOI":"10.3233\/JAD-2011-101977","volume":"26","author":"F Song","year":"2011","unstructured":"Song F, Poljak A, Valenzuela M, Mayeux R, Smythe GA, Sachdev PS. Meta-analysis of plasma amyloid-\u03b2 levels in Alzheimer's disease. J Alzheimer's Dis. 2011;26:365\u201375.","journal-title":"J Alzheimer's Dis"},{"key":"977_CR18","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.3233\/JAD-200475","volume":"77","author":"YY Lim","year":"2020","unstructured":"Lim YY, Maruff P, Kaneko N, Doecke J, Fowler C, Villemagne VL, et al. Plasma amyloid-\u03b2 biomarker associated with cognitive decline in preclinical Alzheimer's disease. J Alzheimer's Dis. 2020;77:1057\u201365.","journal-title":"J Alzheimer's Dis"},{"key":"977_CR19","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/nature25456","volume":"554","author":"A Nakamura","year":"2018","unstructured":"Nakamura A, Kaneko N, Villemagne VL, Kato T, Doecke J, Dor\u00e9 V, et al. High performance plasma amyloid-\u03b2 biomarkers for Alzheimer's disease. Nature. 2018;554:249\u201354.","journal-title":"Nature."},{"key":"977_CR20","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s13195-019-0549-1","volume":"11","author":"V P\u00e9rez-Grijalba","year":"2019","unstructured":"P\u00e9rez-Grijalba V, Arbizu J, Romero J, Prieto E, Pesini P, Sarasa L, et al. Plasma A\u03b242\/40 ratio alone or combined with FDG-PET can accurately predict amyloid-PET positivity: a cross-sectional analysis from the AB255 Study. Alzheimers Res Ther. 2019;11:96.","journal-title":"Alzheimers Res Ther"},{"key":"977_CR21","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-028188","volume":"9","author":"X Li","year":"2019","unstructured":"Li X, Wang X, Su L, Hu X, Han Y. Sino Longitudinal Study on Cognitive Decline (SILCODE): protocol for a Chinese longitudinal observational study to develop risk prediction models of conversion to mild cognitive impairment in individuals with subjective cognitive decline. BMJ Open. 2019;9:e028188.","journal-title":"BMJ Open"},{"key":"977_CR22","doi-asserted-by":"publisher","first-page":"275","DOI":"10.3233\/JAD-140276","volume":"42","author":"MW Bondi","year":"2014","unstructured":"Bondi MW, Edmonds EC, Jak AJ, Clark LR, Delano-Wood L, McDonald CR, et al. Neuropsychological criteria for mild cognitive impairment improves diagnostic precision, biomarker associations, and progression rates. J Alzheimer's Dis. 2014;42:275\u201389.","journal-title":"J Alzheimer's Dis"},{"key":"977_CR23","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","volume":"7","author":"GM McKhann","year":"2011","unstructured":"McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7:263\u20139.","journal-title":"Alzheimers Dement"},{"key":"977_CR24","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0051157","volume":"7","author":"Q Zhao","year":"2012","unstructured":"Zhao Q, Lv Y, Zhou Y, Hong Z, Guo Q. Short-term delayed recall of auditory verbal learning test is equivalent to long-term delayed recall for identifying amnestic mild cognitive impairment. PLoS One. 2012;7:e51157.","journal-title":"PLoS One"},{"key":"977_CR25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0057333","volume":"8","author":"Q Zhao","year":"2013","unstructured":"Zhao Q, Guo Q, Li F, Zhou Y, Wang B, Hong Z. The Shape Trail Test: application of a new variant of the Trail making test. PLoS One. 2013;8:e57333.","journal-title":"PLoS One"},{"key":"977_CR26","first-page":"622","volume":"21","author":"QJL Guo","year":"2007","unstructured":"Guo QJL, Hong Z, Lv C. A specific phenomenon of animal fluency test in chinese elderly. Chin Mental Health J. 2007;21:622\u20135.","journal-title":"Chin Mental Health J"},{"key":"977_CR27","first-page":"81","volume":"20","author":"QHZ Guo","year":"2006","unstructured":"Guo QHZ, Shi W, Sun Y, Lv C. Boston naming test in Chinese elderly, patient with mild cognitive impairment and Alzheimer's dementia. Chin Mental Health J. 2006;20:81\u20134.","journal-title":"Chin Mental Health J"},{"key":"977_CR28","doi-asserted-by":"publisher","first-page":"e285","DOI":"10.1111\/jgs.14530","volume":"64","author":"KL Chen","year":"2016","unstructured":"Chen KL, Xu Y, Chu AQ, Ding D, Liang XN, Nasreddine ZS, et al. Validation of the Chinese version of montreal cognitive assessment basic for screening mild cognitive impairment. J Am Geriatr Soc. 2016;64:e285\u2013e90.","journal-title":"J Am Geriatr Soc"},{"key":"977_CR29","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.bbi.2018.02.016","volume":"70","author":"Y Qian","year":"2018","unstructured":"Qian Y, Yang X, Xu S, Wu C, Song Y, Qin N, et al. Alteration of the fecal microbiota in Chinese patients with Parkinson\u2019s disease. Brain Behav Immun. 2018;70:194\u2013202.","journal-title":"Brain Behav Immun"},{"key":"977_CR30","doi-asserted-by":"publisher","DOI":"10.7717\/peerj.2584","volume":"4","author":"T Rognes","year":"2016","unstructured":"Rognes T, Flouri T, Nichols B, Quince C, Mah\u00e9 F. VSEARCH: a versatile open source tool for metagenomics. PeerJ. 2016;4:e2584.","journal-title":"PeerJ."},{"key":"977_CR31","doi-asserted-by":"publisher","first-page":"2460","DOI":"10.1093\/bioinformatics\/btq461","volume":"26","author":"RC Edgar","year":"2010","unstructured":"Edgar RC. Search and clustering orders of magnitude faster than BLAST. Bioinformatics. 2010;26:2460\u20131.","journal-title":"Bioinformatics."},{"key":"977_CR32","doi-asserted-by":"publisher","first-page":"560","DOI":"10.2967\/jnumed.114.149732","volume":"56","author":"K Chen","year":"2015","unstructured":"Chen K, Roontiva A, Thiyyagura P, Lee W, Liu X, Ayutyanont N, et al. Improved power for characterizing longitudinal amyloid-\u03b2 PET changes and evaluating amyloid-modifying treatments with a cerebral white matter reference region. J Nucl Med. 2015;56:560\u20136.","journal-title":"J Nucl Med"},{"key":"977_CR33","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2020.605734","volume":"8","author":"TR Li","year":"2020","unstructured":"Li TR, Wu Y, Jiang JJ, Lin H, Han CL, Jiang JH, et al. Radiomics analysis of magnetic resonance imaging facilitates the identification of preclinical Alzheimer's Disease: An Exploratory study. Front Cell Dev Biol. 2020;8:605734.","journal-title":"Front Cell Dev Biol"},{"key":"977_CR34","doi-asserted-by":"publisher","first-page":"837","DOI":"10.2307\/2531595","volume":"44","author":"ER DeLong","year":"1988","unstructured":"DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988;44:837\u201345.","journal-title":"Biometrics."},{"key":"977_CR35","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1016\/j.jalz.2016.12.004","volume":"13","author":"H L\u00f6vheim","year":"2017","unstructured":"L\u00f6vheim H, Elgh F, Johansson A, Zetterberg H, Blennow K, Hallmans G, et al. Plasma concentrations of free amyloid \u03b2 cannot predict the development of Alzheimer's disease. Alzheimers Dement. 2017;13:778\u201382.","journal-title":"Alzheimers Dement"},{"key":"977_CR36","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.jalz.2012.12.006","volume":"10","author":"A Rembach","year":"2014","unstructured":"Rembach A, Faux NG, Watt AD, Pertile KK, Rumble RL, Trounson BO, et al. Changes in plasma amyloid beta in a longitudinal study of aging and Alzheimer's disease. Alzheimers Dement. 2014;10:53\u201361.","journal-title":"Alzheimers Dement"},{"key":"977_CR37","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/S1474-4422(16)00070-3","volume":"15","author":"B Olsson","year":"2016","unstructured":"Olsson B, Lautner R, Andreasson U, \u00d6hrfelt A, Portelius E, Bjerke M, et al. CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis. Lancet Neurol. 2016;15:673\u201384.","journal-title":"Lancet Neurol"},{"key":"977_CR38","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/s13195-020-00682-7","volume":"12","author":"IMW Verberk","year":"2020","unstructured":"Verberk IMW, Thijssen E, Koelewijn J, Mauroo K, Vanbrabant J, de Wilde A, et al. Combination of plasma amyloid beta((1-42\/1-40)) and glial fibrillary acidic protein strongly associates with cerebral amyloid pathology. Alzheimers Res Ther. 2020;12:118.","journal-title":"Alzheimers Res Ther"},{"key":"977_CR39","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1093\/nutrit\/nux001","volume":"75","author":"MI Bhat","year":"2017","unstructured":"Bhat MI, Kapila R. Dietary metabolites derived from gut microbiota: critical modulators of epigenetic changes in mammals. Nutr Rev. 2017;75:374\u201389.","journal-title":"Nutr Rev"},{"key":"977_CR40","doi-asserted-by":"crossref","unstructured":"Kumar H, Lund R, Laiho A, Lundelin K, Ley RE, Isolauri E, et al. Gut microbiota as an epigenetic regulator: pilot study based on whole-genome methylation analysis. mBio. 2014;5:e02113\u201314.","DOI":"10.1128\/mBio.02113-14"},{"key":"977_CR41","doi-asserted-by":"crossref","unstructured":"Megur A, Baltriukien\u0117 D, Bukelskien\u0117 V, Burokas A. The microbiota-gut-brain axis and Alzheimer's disease: neuroinflammation is to blame? Nutrients. 2020;13:37.","DOI":"10.3390\/nu13010037"},{"key":"977_CR42","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1126\/science.1223490","volume":"336","author":"LV Hooper","year":"2012","unstructured":"Hooper LV, Littman DR, Macpherson AJ. Interactions between the microbiota and the immune system. Science. 2012;336:1268\u201373.","journal-title":"Science."},{"key":"977_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2020.110112","volume":"106","author":"D Goyal","year":"2021","unstructured":"Goyal D, Ali SA, Singh RK. Emerging role of gut microbiota in modulation of neuroinflammation and neurodegeneration with emphasis on Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry. 2021;106:110112.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"977_CR44","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s12017-019-08547-5","volume":"21","author":"MO Welcome","year":"2019","unstructured":"Welcome MO. Gut microbiota disorder, gut epithelial and blood-brain barrier dysfunctions in etiopathogenesis of dementia: molecular mechanisms and signaling pathways. Neuromolecular Med. 2019;21:205\u201326.","journal-title":"Neuromolecular Med"},{"key":"977_CR45","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.3233\/JAD-170020","volume":"60","author":"L Zhang","year":"2017","unstructured":"Zhang L, Wang Y, Xiayu X, Shi C, Chen W, Song N, et al. Altered gut microbiota in a mouse model of Alzheimer's disease. J Alzheimer's Dis. 2017;60:1241\u201357.","journal-title":"J Alzheimer's Dis"},{"key":"977_CR46","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/nrendo.2015.128","volume":"11","author":"EE Canfora","year":"2015","unstructured":"Canfora EE, Jocken JW, Blaak EE. Short-chain fatty acids in control of body weight and insulin sensitivity. Nat Rev Endocrinol. 2015;11:577\u201391.","journal-title":"Nat Rev Endocrinol"},{"key":"977_CR47","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1080\/19490976.2015.1134082","volume":"7","author":"DJ Morrison","year":"2016","unstructured":"Morrison DJ, Preston T. Formation of short chain fatty acids by the gut microbiota and their impact on human metabolism. Gut Microbes. 2016;7:189\u2013200.","journal-title":"Gut Microbes"},{"key":"977_CR48","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1038\/s41588-019-0350-x","volume":"51","author":"S Sanna","year":"2019","unstructured":"Sanna S, van Zuydam NR, Mahajan A, Kurilshikov A, Vich Vila A, V\u00f5sa U, et al. Causal relationships among the gut microbiome, short-chain fatty acids and metabolic diseases. Nat Genet. 2019;51:600\u20135.","journal-title":"Nat Genet"},{"key":"977_CR49","doi-asserted-by":"publisher","first-page":"25","DOI":"10.3389\/fendo.2020.00025","volume":"11","author":"YP Silva","year":"2020","unstructured":"Silva YP, Bernardi A, Frozza RL. The role of short-chain fatty acids from gut microbiota in gut-brain communication. Front Endocrinol (Lausanne). 2020;11:25.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"977_CR50","doi-asserted-by":"publisher","first-page":"263ra158","DOI":"10.1126\/scitranslmed.3009759","volume":"6","author":"V Braniste","year":"2014","unstructured":"Braniste V, Al-Asmakh M, Kowal C, Anuar F, Abbaspour A, T\u00f3th M, et al. The gut microbiota influences blood-brain barrier permeability in mice. Sci Transl Med. 2014;6:263ra158.","journal-title":"Sci Transl Med"},{"key":"977_CR51","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1007\/s00125-018-4550-1","volume":"61","author":"KH Allin","year":"2018","unstructured":"Allin KH, Tremaroli V, Caesar R, Jensen BAH, Damgaard MTF, Bahl MI, et al. Aberrant intestinal microbiota in individuals with prediabetes. Diabetologia. 2018;61:810\u201320.","journal-title":"Diabetologia."},{"key":"977_CR52","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.3233\/JAD-180176","volume":"63","author":"ZQ Zhuang","year":"2018","unstructured":"Zhuang ZQ, Shen LL, Li WW, Fu X, Zeng F, Gui L, et al. Gut Microbiota is altered in patients with Alzheimer's disease. J Alzheimer's Dis. 2018;63:1337\u201346.","journal-title":"J Alzheimer's Dis"},{"key":"977_CR53","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1111\/1574-6976.12075","volume":"38","author":"M Rajili\u0107-Stojanovi\u0107","year":"2014","unstructured":"Rajili\u0107-Stojanovi\u0107 M, de Vos WM. The first 1000 cultured species of the human gastrointestinal microbiota. FEMS Microbiol Rev. 2014;38:996\u20131047.","journal-title":"FEMS Microbiol Rev"},{"key":"977_CR54","doi-asserted-by":"publisher","first-page":"42","DOI":"10.3389\/fnagi.2018.00042","volume":"10","author":"X Zhan","year":"2018","unstructured":"Zhan X, Stamova B, Sharp FR. Lipopolysaccharide associates with amyloid plaques, neurons and oligodendrocytes in Alzheimer's disease brain: a review. Front Aging Neurosci. 2018;10:42.","journal-title":"Front Aging Neurosci"},{"key":"977_CR55","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.3389\/fmicb.2016.01544","volume":"7","author":"WJ Lukiw","year":"2016","unstructured":"Lukiw WJ. Bacteroides fragilis lipopolysaccharide and inflammatory signaling in Alzheimer's disease. Front Microbiol. 2016;7:1544.","journal-title":"Front Microbiol"},{"key":"977_CR56","doi-asserted-by":"publisher","first-page":"5972","DOI":"10.1099\/ijsem.0.004213","volume":"70","author":"DW Waite","year":"2020","unstructured":"Waite DW, Chuvochina M, Pelikan C, Parks DH, Yilmaz P, Wagner M, et al. Proposal to reclassify the proteobacterial classes Deltaproteobacteria and Oligoflexia, and the phylum Thermodesulfobacteria into four phyla reflecting major functional capabilities. Int J Syst Evol Microbiol. 2020;70:5972\u20136016.","journal-title":"Int J Syst Evol Microbiol"},{"key":"977_CR57","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1158\/1541-7786.MCR-05-0126","volume":"4","author":"MS Attene-Ramos","year":"2006","unstructured":"Attene-Ramos MS, Wagner ED, Plewa MJ, Gaskins HR. Evidence that hydrogen sulfide is a genotoxic agent. Mol Cancer Res. 2006;4:9\u201314.","journal-title":"Mol Cancer Res"},{"key":"977_CR58","doi-asserted-by":"publisher","first-page":"323","DOI":"10.3233\/JAD-200016","volume":"77","author":"C Sheng","year":"2020","unstructured":"Sheng C, Sun Y, Wang M, Wang X, Liu Y, Pang D, et al. Combining visual rating scales for medial temporal lobe atrophy and posterior atrophy to identify amnestic mild cognitive impairment from cognitively normal older adults: evidence based on two cohorts. J Alzheimer's Dis. 2020;77:323\u201337.","journal-title":"J Alzheimer's Dis"},{"key":"977_CR59","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1093\/brain\/aww005","volume":"139","author":"L Harper","year":"2016","unstructured":"Harper L, Fumagalli GG, Barkhof F, Scheltens P, O'Brien JT, Bouwman F, et al. MRI visual rating scales in the diagnosis of dementia: evaluation in 184 post-mortem confirmed cases. Brain. 2016;139:1211\u201325.","journal-title":"Brain."},{"key":"977_CR60","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s13238-020-00724-8","volume":"12","author":"YX Liu","year":"2021","unstructured":"Liu YX, Qin Y, Chen T, Lu M, Qian X, Guo X, et al. A practical guide to amplicon and metagenomic analysis of microbiome data. Protein Cell. 2021;12:315\u201330.","journal-title":"Protein Cell."}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-022-00977-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13195-022-00977-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-022-00977-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,18]],"date-time":"2022-04-18T10:25:24Z","timestamp":1650277524000},"score":1,"resource":{"primary":{"URL":"https:\/\/alzres.biomedcentral.com\/articles\/10.1186\/s13195-022-00977-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,14]]},"references-count":60,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["977"],"URL":"https:\/\/doi.org\/10.1186\/s13195-022-00977-x","relation":{},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,14]]},"assertion":[{"value":"6 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was registered on ClinicalTrials.gov (Identifier: NCT03370744), and research activities were approved by the Medical Research Ethics Committee and Institutional Review Board of Xuanwu Hospital in the Capital Medical University (ID: [2017]046). Each participant needed to provide a written informed consent before participating in study procedures.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"35"}}